New Hope for Infants as Swiss Regulators Approve Treatment for Malaria

Strategic Insights -

In a move hailed by health experts, Swiss medical regulators have approved a new treatment for babies infected with malaria, a parasitic disease that claimed an estimated 597,000 lives worldwide in 2023, predominantly in Africa. The sweet-tasting tablet, known as Coartem Baby, is designed for infants weighing between 2 and 5 kilograms and is a lower dose version of a tablet previously approved for older children. The approval marks a significant development in the fight against malaria, which remains the deadliest disease across Africa, with 1.5 billion people accounting for 95% of global malaria deaths.

Key Takeaways:

  • The new treatment, Coartem Baby, is a combination of two antimalarials and is specifically designed for infants weighing between 2 and 5 kilograms.
  • The approval of Coartem Baby was made by Swissmedic and is in coordination with the World Health Organization (WHO) under a fast-track authorization process to help developing countries access much-needed treatment.
  • Malaria is the deadliest disease in Africa, with 1.5 billion people accounting for 95% of estimated 597,000 malaria deaths worldwide in 2023. Over 75% of those deaths were among children.
  • In Uganda, there were 12.6 million malaria cases and nearly 16,000 deaths in 2023, with many being children under 5 and pregnant women.
  • The Malaria Consortium, a global nonprofit, has welcomed the approval of Coartem Baby as a major leap forward for saving the lives of young children in countries affected by malaria.
  • The treatment will be rolled out in seven countries, including Uganda, Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, and Tanzania.

Statistics:

  • Estimated 597,000 malaria deaths worldwide in 2023, mostly in Africa.
  • 1.5 billion people in Africa accounted for 95% of global malaria deaths in 2023.
  • 12.6 million malaria cases in Uganda in 2023.
  • Nearly 16,000 malaria deaths in Uganda in 2023.
  • Over 75% of malaria deaths in 2023 were among children.

Sources:

  • World Health Organization (WHO)
  • Swissmedic
  • Malaria Consortium
  • The Associated Press

Additional Context:

  • The approval of Coartem Baby is expected to improve treatment outcomes for infants and young children suffering from malaria, a disease that causes significant morbidity and mortality in sub-Saharan Africa.
  • The treatment will be available in public hospitals and private pharmacies, with health workers being trained to administer the medication to infants.
  • Funding for malaria programs remains a challenge, with some countries relying on external sources for support.